New Chemotherapy Regimen Boosts Cervical Cancer Survival Rates

A recent study shows that adding a short course of chemotherapy before standard treatment significantly improves survival for cervical cancer patients.

• The INTERLACE phase III trial found that induction chemotherapy before chemoradiotherapy reduced the risk of death by 40% in cervical cancer patients.
• Conducted over a decade, the study involved 500 patients from five countries and showed an 80% five-year survival rate with the new regimen.
• The trial demonstrated a 35% reduction in cancer recurrence, supporting the integration of this approach into clinical guidelines globally.
• The treatment uses existing, affordable chemotherapy drugs, making it accessible for widespread adoption in various health systems.
• Cervical cancer, primarily caused by HPV, remains a significant health issue, highlighting the importance of vaccination and regular screenings.

3 Articles

CNN Forbes Technology Networks